期刊文献+

高效液相色谱法测定阑尾炎症组织中莫西沙星的浓度 被引量:2

Determination of moxifloxacin concentration in inflammatory appendix tissue by HPLC
原文传递
导出
摘要 目的:建立检测阑尾炎症组织中莫西沙星浓度的高效液相色谱方法。方法:分析柱为Kromasil G8柱,流动相为0.02mol·L^-1磷酸二氢钾溶液-甲醇-乙腈(65:20:15,磷酸调节pH3.0),流速1.0mL·min^-1,检测波长296nm,柱温30℃。阑尾组织匀浆后,以二氯甲烷萃取,挥干,用流动相溶解后进样20μL。结果:莫西沙星组织质量浓度在0.08-10.00mg·L^-1范围内线性关系良好.最低定量限为0.08mg·L^-1,最低检测限0.03mg·L^-1;萃取回收率85.6%~92.4%,方法回收率96.0%~102.5%,日内RSD 2.9%~4.6%,日间RSD 5.2%~9.5%;样品在低温冷冻条件下至少3个月稳定。结论:建立的高效液相色谱法准确可靠.可用于测定莫西沙星在阑尾组织中的浓度及其在阑尾组织中的分布研究。 OBJECTIVE To establish an HPLC method for the determination of moxifloxacin in inflammatory appendix tissue. METHODS The separation was performed on a Kromasil C8 column. The mobile phase was consisted of 0. 02 mol·L^-1 KH2PO4 buffer solution, methanol and acetonitrile (65:20: 15, pH adjusted to 3. 00. The flow rate was 1.0 mL·min^-1 and the detection was 296 nm After the inflammatory appendix tissue was homogenized, moxifloxacin was extracted by methylene chloride and enriched, then 20 μL of redissolved solution was injected to the sampler. RESULTS The calibration curve of moxifloxacin tissue concentration was linear in the range of 0. 08-10.00 mg · L^-1. Limit of quantitation (LOQ) was 0. 08 mg· L^-1 ; Limit of detection (LOD) was 0.03 mg·L ^-1 ; the recovery of extraction was 85.6%- 92.4% and the methodological re covery was 96.0%- 102.5%. RSD for within-day precision and between day precision were 2.9%- 4. 6% and 5.2%-9. 5%, re spectively. The moxifloxacin was stable at least within three months under - 80℃. CONCLUSION The established HPLC method is accurate, sensitive and reliable. It could be used for the determination of moxiflocacin in appendix tissue and the study of its tissue distribution.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2009年第11期907-910,共4页 Chinese Journal of Hospital Pharmacy
基金 深圳市科技计划(医疗卫生类)项目(编号:200803147)
关键词 莫西沙星 阑尾炎 组织浓度 高效液相色谱法 moxicifloxacin appendicitis tissue concentration HPLC
  • 相关文献

参考文献6

  • 1孟静娟.新抗生素莫西沙星国内外研究应用最新进展[J].微生物学杂志,2007,27(5):98-101. 被引量:50
  • 2冷希圣.亚太Dragon研究最新结果证实:莫西沙星(拜复乐)单药可有效治疗cIAI[N].中国医学论坛报,2008-0911.
  • 3Muller M, Amparo DP, Hartmut D. Issue in pharmacokineties and pharmacodynamies of anti-infective agents: distribution in tissue[J].Antimicrobial Agents and Chemotherapy, 2004, 48(5) ; 1411-1453.
  • 4Esposito S, Noviello S, D'Errico G, et al. concentration of moxifloxacin in plasma and tonsillar tissue after muhiple ad ministration in adult patients[J]. J Antimicrob Chemother, 2006,57:789- 792.
  • 5Tatar Ulu S. High-performance liquid chromatography assay for moxifloxacin: Pharmacokinetics in human plasma[J]. J Pharm Biomed Anal, 2007, 43 (1) :320-324.
  • 6Lemoine T, Breilh D, Ducint D, et al. Determination of moxi floxacin (BAY 1228039) in plasma and lung tissue by high performance liquid chromatography with ultraviolet detection using a fully automated extraction method with a new polymeric cartridge[J]. J Chromatogr B, 2000, 742(2): 247- 254.

二级参考文献16

  • 1刘明亮.喹诺酮的演变[J].国外医药(抗生素分册),2006,27(2):69-75. 被引量:16
  • 2Kniaz'kin IV, Aleksandrov VP, Zeziulin PN, et al. Use of avelox in treating urogenital infections in men[ J]. Urologiia. , 2002, (5) :6-8.
  • 3Iakovlcv SV, Ramishvili VSh, Nazarov VV, et al. Efficacy of moxifloxacin in the treatment of secondary peritonitis[J] . Antibiot Khimiotcr. , 2006,51 (5) :3-10.
  • 4Pletz M W, De Roux A, Roth A, et al. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study [ J]. Antimicrob Agents Chemother, 2004, 48: 780-782.
  • 5Gosling R D, Uiso L O, Sam N E, et al. The bactericidal activity of moxifloxaein in patients with pulmonary tuberculosis [J]. Am J Respir Crit Care Med, 2003, 168:1 342-1 345.
  • 6Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis[J]. Int J Tuberc Lung Dis. , 2006,10(6) :591.
  • 7Ogrendik M. Treatment of ankylosing spondylitis with moxifloxacin[J]. South Med J. , 2007,100(4) :366-370.
  • 8Giordano P, Song J, Pertel P, et al. Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection[J]. Int J Antimicrob Agents. , 2005,26(5 ) :357-365.
  • 9Lipsky BA, Giordano P, Choudhri S, Song J Treating diabetic foot infections with sequential intravenous to oral moxifloxacin compared with piperacillin-tazobactam/amoxicillin-clavulanate [J]. Antimicrob Chemother. , 2007 Jun 6.
  • 10Hamasuna R, Osada Y, Jensen J. Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5 ' nuclease real-time PCR [ J]. Antimicrob Agents Chemother, 2005,49 ( 12 ) : 4 993-4 998.

共引文献49

同被引文献9

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部